Lilly to Supply Bamlanivimab to US Government Pending EUA Decision
Bamlanivimab is a potent neutralizing IgG1 monoclonal antibody directed against the spike protein of severe acute respiratory syndrome coronavirus 2.
Bamlanivimab is a potent neutralizing IgG1 monoclonal antibody directed against the spike protein of severe acute respiratory syndrome coronavirus 2.
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
Study authors assessed the relationship between quadrivalent HPV vaccination and risk of invasive cervical cancer and age of vaccination.
An antibody drug for hospitalized COVID-19 patients has been halted because the treatment does not help them recover from their infection.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
The FDA approved Veklury (remdesivir; Gilead Sciences) for the treatment of COVID-19 in patients aged ≥12 years (weighing ≥40kg) requiring hospitalization.
To estimate the association between attribute level and probability of choosing and receiving a vaccine, the study authors calculated the average marginal component effects sizes as well as marginal means.
Regardless of interval or dose level, both heterologous and homologous Ad26, MVA Ebola vaccine regimens were observed to be well tolerated in healthy adults.
Atoltivimab, maftivimab, and odesivimab-ebgn is a combination of Zaire ebolavirus
glycoprotein directed recombinant human IgG1 human monoclonal antibodies.
The efficacy, immunogenicity, and safety of a Clostridioides difficile toxoid vaccine candidate was assessed.